Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.31 |
| ▸ | PARP1 | P09874 | 3/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5660456 | 0.90 | PARP1 (0.33) | BTKPARP1 | |
| SCHEMBL5659643 | 0.89 | L3MBTL3 (0.31) | BTKL3MBTL3L3MBTL1 | |
| SCHEMBL5658727 | 0.83 | BTK (0.36) | BTKL3MBTL3L3MBTL1ITGB3ITGA2B | |
| SCHEMBL5659306 | 0.80 | EGFR (0.31) | BTK | |
| SCHEMBL5660922 | 0.80 | IKBKB (0.40) | BTKL3MBTL3L3MBTL1PARP1F2 | |
| SCHEMBL5661004 | 0.74 | ADRB1 (0.30) | — | |
| SCHEMBL5660062 | 0.74 | BTK (0.33) | BTKL3MBTL3L3MBTL1ITGB3ITGA2B | |
| SCHEMBL5660488 | 0.74 | PARP1 (0.35) | BTKPARP1 | |
| SCHEMBL5660260 | 0.74 | F2 (0.31) | BTKL3MBTL3L3MBTL1ITGB3ITGA2B | |
| SCHEMBL5659437 | 0.73 | BTK (0.36) | BTKPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | claimed |
| US-7205294-B2 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-17 | — | — | US | disclosed |
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227968-A1 | Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions | BDKRB1, BDKRB2, CALCRL | BTK 3872/4885L3MBTL3 4854/4885L3MBTL1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.